Page 27 of 39 · 913 questions tagged clinical-trials.
For reference: oral semaglutide · STEP 2. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have tried to…
The particulars: REDEFINE-1 · ecnoglutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would…
What I am working with: SURMOUNT-2 · 50 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline.…
Numbers first: FLOW · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Numbers first: mazdutide · semaglutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible reason…
Conditions: semaglutide · SELECT. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the question is an…
This came up because two published schedules for the same agent differ. I would like help reading this properly rather than being told what conclusion to reach. I…
What I am working with: SURPASS-3 · cagrilintide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
What I have: mazdutide · retatrutide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible reason…
Setup, so nobody has to ask: PIONEER-1 · mazdutide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…
For reference: tirzepatide · tirzepatide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising for…
Details up front: injection-site erythema · orforglipron · SUSTAIN-6. This is presented as though it settles something, and I am not convinced it does. I have two…
I have been on a stable schedule for eleven weeks, so this is not a first-week question. This is presented as though it settles something, and I am not convinced it…
The specifics, since they change the answer: liraglutide · mazdutide. I am trying to choose between two options that are usually discussed as though only one exists.…
The specifics, since they change the answer: STEP 5 · survodutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody…
Details up front: reflux · retatrutide · ESSENCE. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear…
I have the full paper rather than the abstract, and the supplementary appendix. I understand the observation; what I do not understand is the mechanism behind it. I…
Stated plainly: STEP 4 · injection-site erythema · 2.5 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full…
I have been on a stable schedule for eleven weeks, so this is not a first-week question. This is presented as though it settles something, and I am not convinced it…
The particulars: SURPASS-3 · semaglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
Numbers first: a GLP-1 receptor agonist · tirzepatide. I have used one of these for a while and I am considering switching, which requires a reason. What I care about…
Numbers first: STEP 8 · hair thinning · 50 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
Details up front: reflux · dulaglutide · PIONEER-1. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…
The specifics, since they change the answer: SURMOUNT-OSA · survodutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret…